Abstract
Abstract The anti-neuraminidase antibody (ANAb) response following subcutaneous or intranasal A2/Hong Kong/68 inactivated influenza virus vaccine was evaluated in 81 volunteers of varying ages. Rises in serum ANAb titer were seen in 33 subjects although 76 developed neutralizing antibody rises. In nasal secretions ANAb rises appeared in only 12 subjects as compared with 31 subjects with neutralizing antibody rises. In individual subjects the magnitude of serum ANAb rises to the Hong Kong neuraminidase and an earlier related A2/1957 neuraminidase were similar. Serum and secretory ANAb cross-reacted considerably with neuraminidase antigens of earlier strains of A2 influenza virus. The enzyme inhibition test for ANAb was more sensitive than the hemagglutination inhibition test. ANAb in nasal secretions was IgA. Since ANAb may participate in host defense against influenza virus infection, it may be important to measure the antibody response to the neuraminidase as well as hemagglutinin antigen to select vaccines with optimal prophylactic activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
